Does add-on therapy with Chinese herb medicine Bo-Er-Ning capsule (BENC) improve the outcomes of gastric cancer patients?
| ISRCTN | ISRCTN17186893 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17186893 |
| Protocol serial number | 2-3-84 |
| Sponsor | Zhangqiu People's Hospital of Shandong |
| Funder | Zhangqiu People's Hospital of Shandong |
- Submission date
- 09/03/2018
- Registration date
- 24/03/2018
- Last edited
- 17/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Bo-Er-Ning capsule (BENC) is a traditional Chinese medicine derived from natural products. It is composed of a series of key pharmaceutical ingredients, including Radix Astragali, Fructus Ligustri Lucidi, Tulipaedulis, Herba Portulacae, Rhizoma Paridis , Solanum Nigrum, Fructus Perillae, Corium Stomachichum galli, Rhubarb, Borneol and Bombyx Batryticatus. The aim of this study is to assess the effect of BENC on gastric (stomach) cancer patients.
Who can participate?
Patients aged 25 to 75 with gastric cancer
What does the study involve?
Participants are randomly allocated into two groups: the trial group and the control group. The trial group receive BENC accompanying tegafur and cisplatin drug treatment, while the control group receive tegafur and cisplatin only. Both groups are assessed after three cycles of treatment (each cycle involves 14 days of treatment and 7 days of rest).
What are the possible benefits and risks of participating?
Patients from the trial group may have a better quality of life, such as better appetite and body weight gain, and improved overall survival. As a typical Chinese herb medicine, BENC has been used as an additional medicine for other types of cancer, and no side effects have been reported.
Where is the study run from?
Zhangqiu People's Hospital of Shandong (China)
When is the study starting and how long is it expected to run for?
January 2008 to June 2012
Who is funding the study?
Zhangqiu People's Hospital of Shandong (China)
Who is the main contact?
Prof. Jie He
Contact information
Scientific
Zhangqiu People's Hospital of Shandong
Jinan
250200
China
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single-centre randomized controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Evaluation of the adjuvant therapeutic efficacy of Bo-Er-Ning capsule (BENC) in advanced gastric cancer patients by a randomized clinical trial |
| Study objectives | The addition of BENC to chemotherapy is better than chemotherapy alone. |
| Ethics approval(s) | Ethics board of Zhangqiu People's Hospital of Shandong, 04/03/2008, ref: ZQH/2008/03-1 |
| Health condition(s) or problem(s) studied | Advanced gastric cancer |
| Intervention | All patients with advanced GC treated by FP regimen (Tegafur + Cisplatin) in Zhangqiu People's Hospital of Shandong were enrolled for this clinical study by a doctor participating in the study and randomly divided into two groups by another doctor. Among those, 58 patients received BENC accompanying FP regimen (trial group), while 54 patients received FP regimen alone (control group). Treatment regimen for control group: Tegafur 40~60mg, oral administration, two times a day, from day 1 to day 14 and Cisplatin 40mg, intravenous infusion administration, from day 1 to day 3. Treatment regimen for trial group: BENC 4 capsules, taken orally three times a day (with warm water half an hour after a meal) for 14 days (from day 1 to day 14), accompanying Tegafur and Cisplatin treatment (the same drug dosage and usage as the control group). Both groups were evaluated after 3 cycles (both groups take 21 days as one cycle) of chemotherapy (14 days of treatment and 7 days of rest). |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Tegafur, cisplatin, Bo-Er-Ning capsule |
| Primary outcome measure(s) |
Measured at week 9 (after 3 cycles of chemotherapy): |
| Key secondary outcome measure(s) |
3-year overall survival: patients followed up by clinic visit, phone, or mail at least once every 6 months starting from day 1 after the treatment |
| Completion date | 30/06/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 120 |
| Key inclusion criteria | 1. Age from 25 to 75 years 2. All patients were pathologically confirmed for stage IV or postoperative recurrence and metastasis GC 3. Karnofsky performance score (KPS) ≥ 80 4. No previous anticancer therapy 5. No dysfunction of heart, liver, lung and kidney |
| Key exclusion criteria | 1. Age<25 and >75 years 2. Patients were not pathologically confirmed for stage IV or postoperative recurrence and metastasis GC 3. Karnofsky performance score (KPS) < 80 4. Possess previous anticancer therapy 5. Possess dysfunction of heart, liver, lung and kidney |
| Date of first enrolment | 15/03/2008 |
| Date of final enrolment | 15/09/2008 |
Locations
Countries of recruitment
- China
Study participating centre
China
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available to protect the privacy of the patients. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/06/2018 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
17/01/2019: Publication reference added.
